Assetmark Inc. boosted its position in shares of GSK PLC Sponsored ADR (NYSE:GSK - Free Report) by 35.6% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 101,903 shares of the pharmaceutical company's stock after acquiring an additional 26,754 shares during the period. Assetmark Inc.'s holdings in GSK were worth $3,948,000 at the end of the most recent quarter.
Other hedge funds also recently bought and sold shares of the company. Kingsview Wealth Management LLC lifted its position in shares of GSK by 1.8% during the 1st quarter. Kingsview Wealth Management LLC now owns 15,227 shares of the pharmaceutical company's stock worth $590,000 after purchasing an additional 271 shares during the last quarter. Rehmann Capital Advisory Group increased its position in GSK by 4.6% in the 1st quarter. Rehmann Capital Advisory Group now owns 6,407 shares of the pharmaceutical company's stock worth $248,000 after buying an additional 279 shares during the period. First PREMIER Bank increased its position in GSK by 6.5% in the 1st quarter. First PREMIER Bank now owns 4,659 shares of the pharmaceutical company's stock worth $181,000 after buying an additional 286 shares during the period. Northwest Bank & Trust Co lifted its holdings in shares of GSK by 1.3% during the fourth quarter. Northwest Bank & Trust Co now owns 22,405 shares of the pharmaceutical company's stock worth $765,000 after buying an additional 289 shares during the last quarter. Finally, OneAscent Financial Services LLC boosted its position in shares of GSK by 3.9% in the first quarter. OneAscent Financial Services LLC now owns 7,700 shares of the pharmaceutical company's stock valued at $297,000 after acquiring an additional 292 shares during the period. 15.74% of the stock is currently owned by institutional investors.
GSK Price Performance
Shares of GSK stock traded up $0.20 during mid-day trading on Friday, reaching $37.35. The company's stock had a trading volume of 1,913,021 shares, compared to its average volume of 5,356,486. The firm's 50-day moving average is $38.98 and its two-hundred day moving average is $37.63. The company has a market cap of $76.26 billion, a P/E ratio of 17.29, a PEG ratio of 1.59 and a beta of 0.50. GSK PLC Sponsored ADR has a 1-year low of $31.72 and a 1-year high of $44.67. The company has a debt-to-equity ratio of 1.21, a quick ratio of 0.58 and a current ratio of 0.87.
GSK (NYSE:GSK - Get Free Report) last posted its quarterly earnings results on Wednesday, July 30th. The pharmaceutical company reported $1.23 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.12 by $0.11. The firm had revenue of $10.64 billion during the quarter, compared to analyst estimates of $7.92 billion. GSK had a net margin of 10.81% and a return on equity of 50.68%. The company's quarterly revenue was up 1.3% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.43 earnings per share. On average, research analysts predict that GSK PLC Sponsored ADR will post 4.14 earnings per share for the current year.
GSK Cuts Dividend
The business also recently announced a quarterly dividend, which will be paid on Thursday, October 9th. Investors of record on Friday, August 15th will be given a dividend of $0.4206 per share. This represents a $1.68 annualized dividend and a dividend yield of 4.5%. The ex-dividend date is Friday, August 15th. GSK's dividend payout ratio (DPR) is 79.17%.
Analyst Ratings Changes
A number of brokerages recently issued reports on GSK. Wall Street Zen lowered shares of GSK from a "buy" rating to a "hold" rating in a research report on Saturday, July 26th. Berenberg Bank restated a "hold" rating on shares of GSK in a report on Tuesday, June 3rd. BNP Paribas began coverage on shares of GSK in a research note on Tuesday, April 15th. They issued a "neutral" rating and a $35.25 target price for the company. Finally, Hsbc Global Res upgraded GSK to a "strong sell" rating in a research note on Monday, April 28th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, GSK currently has an average rating of "Hold" and a consensus target price of $37.38.
Check Out Our Latest Stock Analysis on GSK
GSK Company Profile
(
Free Report)
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.
Further Reading
Before you consider GSK, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GSK wasn't on the list.
While GSK currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
